SAB Biotherapeutics, Inc. (SABS) Form 10-Q — May 12, 2026
SAB Biotherapeutics, Inc. reported a net loss of $18.87 million for the three months ended March 31, 2026, compared to a net loss of $5.20 million for the same period in 2025. This increase in loss is primarily due to higher research and development expenses, which rose by 75.0% to $13.40 million, and higher general and administrative expenses, which increased by 111.9% to $6.60 million. The company's cash and cash equivalents increased to $20.52 million as of March 31, 2026, from $10.50 million as of December 31, 2025.
Key figures
- Eps
- -0.35
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -18,868,885
- Total Debt
- 21,222,197
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 248,470,498
- Cash Position
- 20,519,724
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 76,464,094
- Accumulated Deficit
- -129,764,052
- Australian Tax Credit Income
- 100,000
- Tranche CPreferred Warrants
- 5,962,067
- Research And Development Expenses
- 13,397,977
- General And Administrative Expenses
- 6,599,759
- Net Cash Used In Operating Activities
- -14,271,130
- Private Placement Warrant Liability
- 5,445
- Net Increase In Cash And Cash Equivalents
- 10,017,044
- Net Cash Provided By Financing Activities
- 89,921,121
- Net Cash Provided By Investing Activities
- -65,647,676
Price after filing
Close on the filing date to close N calendar days later (from $3.62). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.